Fabry
Fabry disease is a rare genetic disorder that results from the buildup of a particular type of fat, known as globotriaosylceramide, in the body's cells. It is one of several lipid storage disorders and is caused by a deficiency of the enzyme alpha-galactosidase A (α-Gal A).
Symptoms[edit | edit source]
The symptoms of Fabry disease can range from mild to severe and can appear anytime from childhood to adulthood. Common symptoms include pain, particularly in the hands and feet; clusters of small, dark red spots on the skin; a decreased ability to sweat; cloudiness of the front part of the eye; gastrointestinal problems; ringing in the ears; and hearing loss.
Causes[edit | edit source]
Fabry disease is caused by mutations in the GLA gene. This gene provides instructions for producing the enzyme alpha-galactosidase A, which is responsible for breaking down a specific type of fat molecule called globotriaosylceramide. Mutations in the GLA gene lead to a shortage (deficiency) of alpha-galactosidase A, causing globotriaosylceramide to accumulate in cells throughout the body, particularly cells lining blood vessels in the skin and cells in the kidneys, heart, and nervous system.
Diagnosis[edit | edit source]
Diagnosis of Fabry disease can be challenging because its symptoms are often nonspecific, meaning they could be caused by a variety of conditions. The diagnosis is usually confirmed by measuring the level of alpha-galactosidase A activity in a person's blood or tissues. Genetic testing can also be used to identify mutations in the GLA gene.
Treatment[edit | edit source]
There is currently no cure for Fabry disease, but treatments are available to help manage symptoms and slow the progression of the disease. These treatments include enzyme replacement therapy (ERT), which involves infusing a recombinant form of the alpha-galactosidase A enzyme into a person's bloodstream, and chaperone therapy, which uses small molecules to help the body's own alpha-galactosidase A work more effectively.
See also[edit | edit source]
References[edit | edit source]
| Fabry Resources | |
|---|---|
|
 |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
